Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Tirbanibulin (Klisyri) is indicated for the topical treatment of actinic keratosis of the face or scalp. It has been assessed across multiple documents for its role in treating this condition, focusing on its effectiveness and safety profile.
• Three systematic reviews/meta-analyses were reviewed to gather information about Klisyri's comparative effectiveness and safety profiles against various treatments for actinic keratosis.
• In terms of comparison to other treatments, tirbanibulin received a clinical recommendation grade C, placing it alongside calcipotriol/5-fluorouracil, imiquimod, and combination therapies involving sunscreen but behind 5-Fluorouracil/salicylic acid (grade A) and diclofenac sodium (grade B).
• The Bayesian network meta-analysis suggests that while fluorouracil 5% and photodynamic therapy with aminolevulinic acid have higher odds ratios indicating greater efficacy, tirbanibulin also shows promising results with an odds ratio of 11.1, suggesting competitive effectiveness.
• Regarding safety and tolerability, newer agents like tirbanibulin are reported to have more favorable safety profiles compared to older treatments such as 5-FU and imiquimod, according to one study specifically addressing these aspects among FDA-approved topical agents for AK.
• While detailed subgroup analyses based on age, gender, or severity are not explicitly discussed; overall evaluations suggest that the therapeutic landscape involves selecting treatment options that balance efficacy with safety and tolerability, implying considerations for use in populations prioritizing minimal side effects or having concerns regarding tolerability.